Literature DB >> 35840705

From the prodromal stage of multiple sclerosis to disease prevention.

Ruth Ann Marrie1,2, Mark Allegretta3, Lisa F Barcellos4,5, Bruce Bebo3, Peter A Calabresi6, Jorge Correale7, Benjamin Davis8, Philip L De Jager9, Christiane Gasperi10, Carla Greenbaum11, Anne Helme12, Bernhard Hemmer10,13, Pamela Kanellis8, Walter Kostich3, Douglas Landsman3, Christine Lebrun-Frenay14, Naila Makhani15, Kassandra L Munger16, Darin T Okuda17, Daniel Ontaneda18, Ronald B Postuma19, Jacqueline A Quandt20, Sharon Roman21, Shiv Saidha22, Maria Pia Sormani23, Jon Strum24, Pamela Valentine8, Clare Walton25, Kathleen M Zackowski3, Yinshan Zhao26, Helen Tremlett26.   

Abstract

A prodrome is an early set of signs or symptoms that indicate the onset of a disease before more typical symptoms develop. Prodromal stages are well recognized in some neurological and immune-mediated diseases such as Parkinson disease, schizophrenia, type 1 diabetes mellitus and rheumatoid arthritis. Emerging evidence indicates that a prodromal stage exists in multiple sclerosis (MS), raising the possibility of intervention at this stage to delay or prevent the development of classical MS. However, much remains unclear about the prodromal stage of MS and considerable research is needed to fully characterize the prodrome and develop standardized criteria to reliably identify individuals with prodromal MS who are at high risk of progressing to a diagnosis of MS. In this Roadmap, we draw on work in other diseases to propose a disease framework for MS that incorporates the prodromal stage, and set out key steps and considerations needed in future research to fully characterize the MS prodrome, identify early disease markers and develop standardized criteria that will enable reliable identification of individuals with prodromal MS, thereby facilitating trials of interventions to slow or stop progression beyond the prodrome.
© 2022. Springer Nature Limited.

Entities:  

Mesh:

Year:  2022        PMID: 35840705     DOI: 10.1038/s41582-022-00686-x

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   44.711


  88 in total

Review 1.  MDS research criteria for prodromal Parkinson's disease.

Authors:  Daniela Berg; Ronald B Postuma; Charles H Adler; Bastiaan R Bloem; Piu Chan; Bruno Dubois; Thomas Gasser; Christopher G Goetz; Glenda Halliday; Lawrence Joseph; Anthony E Lang; Inga Liepelt-Scarfone; Irene Litvan; Kenneth Marek; José Obeso; Wolfgang Oertel; C Warren Olanow; Werner Poewe; Matthew Stern; Günther Deuschl
Journal:  Mov Disord       Date:  2015-10       Impact factor: 10.338

Review 2.  Preclinical Rheumatoid Arthritis: Progress Toward Prevention.

Authors:  Kulveer Mankia; Paul Emery
Journal:  Arthritis Rheumatol       Date:  2016-04       Impact factor: 10.995

Review 3.  Early intervention and the treatment of prodrome in schizophrenia: a review of recent developments.

Authors:  Mohammadreza Mokhtari; Rajaprabhakaran Rajarethinam
Journal:  J Psychiatr Pract       Date:  2013-09       Impact factor: 1.325

4.  Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis.

Authors:  Eduardo Beltrán; Lisa Ann Gerdes; Julia Hansen; Andrea Flierl-Hecht; Stefan Krebs; Helmut Blum; Birgit Ertl-Wagner; Frederik Barkhof; Tania Kümpfel; Reinhard Hohlfeld; Klaus Dornmair
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

5.  Presentation to primary care during the prodrome of type 1 diabetes in childhood: A case-control study using record data linkage.

Authors:  Julia Townson; Rebecca Cannings-John; Nick Francis; Dan Thayer; John W Gregory
Journal:  Pediatr Diabetes       Date:  2019-03-07       Impact factor: 4.866

6.  Preclinical disease activity in multiple sclerosis: A prospective study of cognitive performance prior to first symptom.

Authors:  Marianna Cortese; Trond Riise; Kjetil Bjørnevik; Alok Bhan; Elisabeth Farbu; Nina Grytten; Ineke Hogenesch; Rune Midgard; Cecilia Smith Simonsen; Wenche Telstad; Alberto Ascherio; Kjell-Morten Myhr
Journal:  Ann Neurol       Date:  2016-10       Impact factor: 10.422

7.  Assessment of Early Evidence of Multiple Sclerosis in a Prospective Study of Asymptomatic High-Risk Family Members.

Authors:  Zongqi Xia; Sonya U Steele; Anshika Bakshi; Sarah R Clarkson; Charles C White; Matthew K Schindler; Govind Nair; Blake E Dewey; Lauren R Price; Joan Ohayon; Lori B Chibnik; Irene C M Cortese; Philip L De Jager; Daniel S Reich
Journal:  JAMA Neurol       Date:  2017-03-01       Impact factor: 18.302

8.  Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study.

Authors:  José M A Wijnands; Elaine Kingwell; Feng Zhu; Yinshan Zhao; Tanja Högg; Karen Stadnyk; Okechukwu Ekuma; Xinya Lu; Charity Evans; John D Fisk; Ruth Ann Marrie; Helen Tremlett
Journal:  Lancet Neurol       Date:  2017-04-20       Impact factor: 44.182

9.  Prodromal symptoms of multiple sclerosis in primary care.

Authors:  Giulio Disanto; Chiara Zecca; Sharon MacLachlan; Rosaria Sacco; Lahiru Handunnetthi; Ute C Meier; Alex Simpson; Laura McDonald; Andrea Rossi; Pascal Benkert; Jens Kuhle; Sreeram V Ramagopalan; Claudio Gobbi
Journal:  Ann Neurol       Date:  2018-05-30       Impact factor: 10.422

10.  High rates of health care utilization in pediatric multiple sclerosis: A Canadian population-based study.

Authors:  Ruth Ann Marrie; Julia O'Mahony; Colleen J Maxwell; Vicki Ling; E Ann Yeh; Douglas L Arnold; Amit Bar-Or; Brenda Banwell
Journal:  PLoS One       Date:  2019-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.